CD274 and small cell lung carcinoma: In the absence of head-to-head RCTs comparing PD-L1 inhibitors with PD-L1 inhibitors plus chemotherapy in the first-line treatment of ES-SCLC, this study provides the available high-level evidence for clinical decision.